Loomis, Sayles & Company
BBIO icon

Loomis, Sayles & Company’s BridgeBio Pharma BBIO Stock Holding History

Loomis, Sayles & Company’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-408,562
Closed -$19.1M – 780
2021
Q3 		$19.1M Buy
408,562
+113,537
+38% +$6.09M 0.02% 308
2021
Q2 		$18M Buy
+295,025
New +$16.8M 0.02% 315

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Loomis, Sayles & Company's BBIO Position: Q4 2021 in Review

Loomis, Sayles & Company sold out of BridgeBio Pharma (BBIO) in Q4 2021, closing a stake of 408,562 shares — an estimated $19.1M sold.

Loomis, Sayles & Company first reported a position in BBIO in Q2 2021 and held it in 2 quarters. The position peaked at $19.1M in Q3 2021. 195 funds tracked by Wall St. Rank hold BBIO as of Q4 2021.

  • Loomis, Sayles & Company reported no remaining BridgeBio Pharma position as of Q4 2021 after selling out during the quarter.
  • Loomis, Sayles & Company sold 408,562 BridgeBio Pharma shares in Q4 2021, an estimated $19.1M.
  • Loomis, Sayles & Company first reported a position in BridgeBio Pharma in Q2 2021 and held it in 2 quarters.
  • Loomis, Sayles & Company's BridgeBio Pharma position peaked at $19.1M in Q3 2021.
  • 195 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2021.

Based on Loomis, Sayles & Company's 13F filing for Q4 2021, filed 14 Feb 2022.